Genomictree Inc. (228760) - Net Assets
Based on the latest financial reports, Genomictree Inc. (228760) has net assets worth ₩115.31 Billion KRW (≈ $78.14 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩120.76 Billion ≈ $81.84 Million USD) and total liabilities (₩5.45 Billion ≈ $3.69 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 228760 total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩115.31 Billion |
| % of Total Assets | 95.49% |
| Annual Growth Rate | 3.9% |
| 5-Year Change | 0.18% |
| 10-Year Change | N/A |
| Growth Volatility | 11.95 |
Genomictree Inc. - Net Assets Trend (2020–2025)
This chart illustrates how Genomictree Inc.'s net assets have evolved over time, based on quarterly financial data. Check 228760 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Genomictree Inc. (2020–2025)
The table below shows the annual net assets of Genomictree Inc. from 2020 to 2025. For live valuation and market cap data, see 228760 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩115.31 Billion ≈ $78.14 Million |
-7.25% |
| 2024-12-31 | ₩124.32 Billion ≈ $84.25 Million |
-0.57% |
| 2023-12-31 | ₩125.03 Billion ≈ $84.73 Million |
+16.79% |
| 2022-12-31 | ₩107.05 Billion ≈ $72.55 Million |
-6.99% |
| 2021-12-31 | ₩115.10 Billion ≈ $78.00 Million |
+20.83% |
| 2020-12-31 | ₩95.26 Billion ≈ $64.55 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Genomictree Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4434733640000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩12.04 Billion | 10.46% |
| Other Components | ₩103.03 Billion | 89.54% |
| Total Equity | ₩115.07 Billion | 100.00% |
Genomictree Inc. Competitors by Market Cap
The table below lists competitors of Genomictree Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HomeToGo SE
F:HTG
|
$190.93 Million |
|
Doosan Co Ltd
KO:000157
|
$191.02 Million |
|
Amway (Malaysia) Holdings Bhd
KLSE:6351
|
$191.09 Million |
|
Akwel SA
PA:AKW
|
$191.12 Million |
|
Adgar Investments and Development Ltd
TA:ADGR
|
$190.90 Million |
|
Tah Hsin Industrial Corp
TW:1315
|
$190.81 Million |
|
Tian Zheng International Precision Machinery Co Ltd
TWO:6654
|
$190.77 Million |
|
CHINA KEPEI ED. DL-00001
F:9CK
|
$190.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genomictree Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 123,884,817,630 to 115,069,631,630, a change of -8,815,186,000 (-7.1%).
- Net loss of 8,985,720,490 reduced equity.
- New share issuances of 231,957,320 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-8.99 Billion | -7.81% |
| Share Issuances | ₩231.96 Million | +0.2% |
| Other Changes | ₩-61.42 Million | -0.05% |
| Total Change | ₩- | -7.12% |
Book Value vs Market Value Analysis
This analysis compares Genomictree Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.45x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | ₩4766.06 | ₩11730.00 | x |
| 2021-12-31 | ₩5662.32 | ₩11730.00 | x |
| 2022-12-31 | ₩5185.29 | ₩11730.00 | x |
| 2023-12-31 | ₩5278.29 | ₩11730.00 | x |
| 2024-12-31 | ₩5163.99 | ₩11730.00 | x |
| 2025-12-31 | ₩4791.19 | ₩11730.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genomictree Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -238.98%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.05x
- Recent ROE (-7.81%) is above the historical average (-8.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -12.38% | -952.10% | 0.01x | 1.24x | ₩-21.32 Billion |
| 2021 | -9.93% | -222.28% | 0.03x | 1.54x | ₩-22.93 Billion |
| 2022 | -6.19% | -22.20% | 0.18x | 1.52x | ₩-17.34 Billion |
| 2023 | -7.02% | -256.17% | 0.03x | 1.06x | ₩-21.23 Billion |
| 2024 | -8.27% | -433.57% | 0.02x | 1.05x | ₩-22.63 Billion |
| 2025 | -7.81% | -238.98% | 0.03x | 1.05x | ₩-20.49 Billion |
Industry Comparison
This section compares Genomictree Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $256,967,939,787
- Average return on equity (ROE) among peers: -5.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genomictree Inc. (228760) | ₩115.31 Billion | -12.38% | 0.05x | $190.92 Million |
| ORIENTBIO Inc. (002630) | $60.51 Billion | 0.00% | 1.04x | $69.59 Million |
| Green Cross (005250) | $350.47 Billion | 6.04% | 6.94x | $285.94 Million |
| Green Cross Holdings Preference Shares (005257) | $1.88 Trillion | -2.88% | 0.99x | $2.32 Million |
| Pharmicell (005690) | $76.66 Billion | 10.78% | 0.43x | $418.84 Million |
| GeneOne Life Science Inc (011000) | $36.54 Billion | -64.94% | 0.25x | $164.07 Million |
| HLB Co. Ltd (028300) | $15.50 Billion | 0.00% | 1.33x | $2.78 Billion |
| Mgenplus Co. Ltd. (032790) | $17.78 Billion | 0.00% | 1.54x | $16.18 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $19.73 Billion | 2.26% | 0.29x | $15.25 Million |
| Seoulin Bioscience Co.Ltd (038070) | $59.71 Billion | 14.88% | 0.35x | $24.62 Million |
| Hyundai Bioscience Co. Ltd (048410) | $51.22 Billion | -16.80% | 0.80x | $403.52 Million |
About Genomictree Inc.
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect … Read more